Cor Therapeutics, Inc. names Mark Perrin Executive Vice President, Commercial Operations.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BUSINESS WIRE)--Nov. 27, 1995-- COR Therapeutics, Inc. (Nasdaq: CORR CORR Used on the consolidated tape to indicate a correction in a reported transaction : CORR.LAST.GY 50 WAS 51. ) today announced that Mark D. Perrin has joined the Company as Executive Vice President, Commercial Operations. In this newly created position, Mr. Perrin will be responsible for all aspects of commercialization and marketing and will report directly to the Company's President and CEO, Vaughn M. Kailian. Most recently, Mr. Perrin, age 39, served as Vice President, Marketing and Sales of Burroughs Wellcome Company, from 1992 to 1995. In this capacity, he was responsible for management of all marketing and sales operations for Burroughs Wellcome in the United States. From 1979 to 1992, he held various sales and marketing positions at Lederle Laboratories/American Cyanamid cy·an·am·ide also cy·an·am·id n. 1. A caustic acidic crystalline compound, NHCNH, prepared by treating calcium cyanamide with sulfuric acid. 2. Calcium cyanamide. Noun 1. Company, including Vice President and General Manager of Lederle Pharmaceuticals, Vice President and General Manager of Lederle Consumer Health Products, and Division Manager of Lederle Laboratories in Canada. Mr. Perrin received his undergraduate degree from Fordham University and his graduate degree from the Kellog Graduate School of Management, Northwestern University. COR Therapeutics, Inc. is dedicated to the discovery, development and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. COR has complementary product development programs that address critical needs in severe cardiovascular care, including unstable angina, acute myocardial infarction acute myocardial infarction ( CONTACT: COR Therapeutics, Inc. Laura A. Brege, 415/244-6893 or Burns McClellan Justin Jackson, 415/352-6262 |
|
||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion